パーキンソン病治療薬の市場規模、シェア、成長分析、薬剤クラス別、投与方法別、年齢別、地域別 - 産業予測、2025～2032年

パーキンソン病治療薬の世界市場規模は2023年に46億米ドルと評価され、2024年の50億9,000万米ドルから2032年には113億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは10.6％で成長する見通しです。

世界のパーキンソン病治療薬市場は、ドーパミンの産生が低下し、震えやこわばりのような症状を特徴とするこの神経疾患に罹患している患者が現在1,000万人を超えることから、大きな成長が見込まれています。この疾患の有病率が上昇し、効果的な症状管理の必要性が高まり続ける中、市場は併用療法、徐放性薬剤、遺伝子治療の進歩、政府からの支援金に対する関心の高まりから利益を得ています。さらに、高齢化、ヘルスケアシステムの改善、継続的な研究開発などの要因が市場開拓を後押ししています。ブランド薬の特許切れや新規治療の強力なパイプラインは、予測期間中、業界の企業に有利な機会をもたらし、市場の可能性をさらに高めています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

パーキンソン病治療薬市場規模：薬剤クラス別

• 市場概要
• 脱炭酸酵素阻害剤
• ドーパミン作動薬
• COMT阻害剤
• MAO-B阻害剤
• その他

パーキンソン病治療薬市場規模：投与方法別

• 市場概要
• 経口
• 注射
• 経皮

パーキンソン病治療薬市場規模：年齢別

• 市場概要
• 50歳未満
• 50歳以上

パーキンソン病治療薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• UCB S.A.（Belgium）
• GlaxoSmithKline plc（UK）
• Merck & Co., Inc.（USA）
• Boehringer Ingelheim（Germany）
• Lundbeck A/S（Denmark）
• Acadia Pharmaceuticals Inc.（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Amneal Pharmaceuticals, Inc.（USA）
• Supernus Pharmaceuticals, Inc.（USA）
• Kyowa Kirin Co., Ltd.（Japan）
• Orion Corporation（Finland）
• Neurocrine Biosciences, Inc.（USA）
• Acorda Therapeutics, Inc.（USA）
• Ipsen S.A.（France）
• Luye Pharma Group（China）
• NeuroDerm Ltd.（Israel）（acquired by Mitsubishi Tanabe Pharma）
• Revance Therapeutics, Inc.（USA）

結論と推奨事項

Global Parkinson'S Disease Drug Market size was valued at USD 4.6 billion in 2023 and is poised to grow from USD 5.09 billion in 2024 to USD 11.39 billion by 2032, growing at a CAGR of 10.6% during the forecast period (2025-2032).

The global Parkinson's disease drug market is poised for significant growth, driven by over 10 million individuals currently affected by this neurological disorder, characterized by declining dopamine production and symptoms like tremors and stiffness. As the disease's prevalence rises and the need for effective symptom management continues to grow, the market is benefiting from increased interest in combination therapies, extended-release medications, gene therapy advancements, and supportive government funding. Additionally, factors such as an aging population, improved healthcare systems, and ongoing research and development are bolstering market expansion. The expiration of patents for branded drugs and a strong pipeline of new treatments present lucrative opportunities for industry players during the forecast period, further enhancing the market's potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Parkinson'S Disease Drug market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Parkinson'S Disease Drug Market Segmental Analysis

Global Parkinson'S Disease Drug Market is segmented by drug class, administration, age and region. Based on drug class, the market is segmented into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-b inhibitors and others. Based on administration, the market is segmented into oral, injection and transdermal. Based on age, the market is segmented into < 50 years and > 50 years. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Parkinson'S Disease Drug Market

The global Parkinson's Disease drug market is significantly influenced by several key drivers. Foremost among them is the growing aging population alongside the escalating incidence of Parkinson's disease. As the demographic landscape shifts with an increasing number of elderly individuals, the prevalence of neurological disorders, including Parkinson's, is on the rise. This surge in patient numbers directly correlates with a heightened demand for effective treatment options, thus propelling the market's growth. As a result, this dynamic is anticipated to positively impact the expansion of the Parkinson's Disease drug market worldwide throughout the forecast period.

Restraints in the Global Parkinson'S Disease Drug Market

The global market for Parkinson's disease drugs faces significant restraints primarily due to the high costs associated with treatment. As the prevalence of Parkinson's disease continues to rise, the financial burden on patients, families, and healthcare systems is becoming increasingly pronounced. This economic strain often poses a barrier to accessing necessary treatments and medications, thereby inhibiting the overall growth of the market. Consequently, the prohibitive expense of managing Parkinson's disease is anticipated to serve as a critical challenge for market expansion throughout the forecast period, impacting both patient care and the availability of new therapeutic options.

Market Trends of the Global Parkinson'S Disease Drug Market

The Global Parkinson's Disease Drug market is experiencing substantial growth, driven by a notable surge in research and development funding from both government and corporate sectors aimed at advancing treatment options. This trend is propelling pharmaceutical companies to innovate and introduce new therapeutic drugs that address symptom management and disease modification. Increasing awareness and diagnosis of Parkinson's disease, coupled with a rising geriatric population, further catalyze market expansion. As investments in novel drug development grow, the market is poised for sustained growth, reflecting the increasing commitment to improving patient outcomes and enhancing the quality of life for those affected by Parkinson's disease.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Parkinson's Disease Drug Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Decarboxylase Inhibitors
• Dopamine Agonists
• COMT Inhibitors
• MAO-B Inhibitors
• Others

Global Parkinson's Disease Drug Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection
• Transdermal

Global Parkinson's Disease Drug Market Size by Age & CAGR (2025-2032)

• Market Overview
• < 50 Years
• >50 Years

Global Parkinson's Disease Drug Market Size & CAGR (2025-2032)

• North America (Drug Class, Administration, Age)
  • US
  • Canada
• Europe (Drug Class, Administration, Age)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Administration, Age)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Administration, Age)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Administration, Age)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Supernus Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Corporation (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acorda Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company OvervSiew
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luye Pharma Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroDerm Ltd. (Israel) (acquired by Mitsubishi Tanabe Pharma)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revance Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations